The COVAC-2 vaccine's favorable safety and immunogenicity profile positions it as a competitive option for COVID-19 booster vaccinations, particularly in resource-limited settings. This development necessitates strategic evaluation by pharma companies regarding their existing vaccine portfolios and market positioning. Regulatory context from FDA (New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)) supports the near-term read. Assessment grounded in 18 ranked evidence items (3 high-relevance).